Video
Author(s):
Treatment following progression on chemotherapy and an immune checkpoint inhibitor remains an unmet medical need.
Thomas Powles, MBBS, MRCP, MD, director, Barts Cancer Institute, discusses standard treatment for patients with metastatic urothelial cancer in the frontline setting and beyond.
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.